IN2014DN09050A - - Google Patents
Info
- Publication number
- IN2014DN09050A IN2014DN09050A IN9050DEN2014A IN2014DN09050A IN 2014DN09050 A IN2014DN09050 A IN 2014DN09050A IN 9050DEN2014 A IN9050DEN2014 A IN 9050DEN2014A IN 2014DN09050 A IN2014DN09050 A IN 2014DN09050A
- Authority
- IN
- India
- Prior art keywords
- site
- dosing regimen
- nerve block
- prolonged
- stx
- Prior art date
Links
- 208000004454 Hyperalgesia Diseases 0.000 abstract 3
- 210000005036 nerve Anatomy 0.000 abstract 3
- 230000002035 prolonged effect Effects 0.000 abstract 3
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 abstract 3
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 abstract 3
- 208000035154 Hyperesthesia Diseases 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 2
- 239000003246 corticosteroid Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000002502 liposome Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229940125794 sodium channel blocker Drugs 0.000 abstract 2
- 239000003195 sodium channel blocking agent Substances 0.000 abstract 2
- 231100000057 systemic toxicity Toxicity 0.000 abstract 2
- 206010053552 allodynia Diseases 0.000 abstract 1
- 230000001934 delay Effects 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261637156P | 2012-04-23 | 2012-04-23 | |
| PCT/US2013/037838 WO2013163214A1 (en) | 2012-04-23 | 2013-04-23 | Formulations and methods for delaying onset of chronic neuropathic pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09050A true IN2014DN09050A (de) | 2015-05-22 |
Family
ID=48227582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9050DEN2014 IN2014DN09050A (de) | 2012-04-23 | 2013-04-23 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9408846B2 (de) |
| EP (1) | EP2841071A1 (de) |
| JP (1) | JP2015514805A (de) |
| CN (1) | CN104427987A (de) |
| IN (1) | IN2014DN09050A (de) |
| WO (1) | WO2013163214A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201602576D0 (en) | 2016-02-12 | 2016-03-30 | Bergen Teknologioverforing As | Process |
| CN105919979B (zh) * | 2016-06-28 | 2019-07-02 | 国家海洋局第三海洋研究所 | 一种替曲朵辛肠溶缓释微丸、制备方法及其应用 |
| CN107115298A (zh) * | 2017-05-22 | 2017-09-01 | 黄海枫 | 一种ttx鱼肝油乳剂 |
| AU2018375002B2 (en) * | 2017-12-01 | 2021-11-11 | The Children's Medical Center Corporation | Covalent anesthetic-polymer conjugates for prolonged local anesthesia |
| WO2019113184A1 (en) * | 2017-12-06 | 2019-06-13 | Children's Medical Center Corporation | Nanoparticles for nerve penetration and uses thereof |
| KR101841654B1 (ko) * | 2017-12-19 | 2018-03-26 | (주)나노스템 | 콜린 알포세레이트를 유효성분으로 하는 신경병증성 통증의 치료, 개선 또는 예방용 조성물 및 방법 |
| EP4706665A1 (de) * | 2023-05-05 | 2026-03-11 | Xiangya Hospital, Central South University | Magnesiumhydroxidnanopartikel zur behandlung von arthroalgie sowie herstellungsverfahren dafür und verwendung davon |
| CN117562869B (zh) * | 2023-05-05 | 2024-07-16 | 中南大学湘雅医院 | 一种治疗关节疼痛的氢氧化镁纳米粒、其制备方法及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1111453A (zh) | 1993-07-01 | 1995-11-08 | 日本钢管株式会社 | 芳基磺酰胺衍生物及含该衍生物的药物组合物 |
| US5776488A (en) * | 1994-03-11 | 1998-07-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Liposome preparation |
| US5747060A (en) * | 1996-03-26 | 1998-05-05 | Euro-Celtique, S.A. | Prolonged local anesthesia with colchicine |
| US6210707B1 (en) * | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| AU7389098A (en) | 1997-05-16 | 1998-12-08 | Brigham And Women's Hospital | Local anesthetic formulations |
| US8853452B2 (en) | 2009-02-10 | 2014-10-07 | The Administrators Of The Tulane Educational Fund | Compounds, their syntheses, compositions, and methods to treat cancer |
| US20120034296A1 (en) | 2009-04-08 | 2012-02-09 | Massachusetts Institute Of Technology | Prolonged duration local anesthesia with minimal toxicity |
-
2013
- 2013-04-23 IN IN9050DEN2014 patent/IN2014DN09050A/en unknown
- 2013-04-23 CN CN201380032990.0A patent/CN104427987A/zh active Pending
- 2013-04-23 EP EP13719692.9A patent/EP2841071A1/de not_active Withdrawn
- 2013-04-23 US US14/396,316 patent/US9408846B2/en not_active Expired - Fee Related
- 2013-04-23 JP JP2015509084A patent/JP2015514805A/ja active Pending
- 2013-04-23 WO PCT/US2013/037838 patent/WO2013163214A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013163214A1 (en) | 2013-10-31 |
| CN104427987A (zh) | 2015-03-18 |
| US20150079159A1 (en) | 2015-03-19 |
| EP2841071A1 (de) | 2015-03-04 |
| JP2015514805A (ja) | 2015-05-21 |
| US9408846B2 (en) | 2016-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| PH12020500336A1 (en) | FORMULATION FOR ANTI-a4á7 ANTIBODY | |
| PH12017501774A1 (en) | Compositions comprising a combination of an anti-pd-1 antibody and another antibody | |
| EP4058190A4 (de) | Zusammensetzungen und verfahren zur kontrollierten abgabe und zum schutz von therapeutika | |
| MY188139A (en) | Sodium channel modulators for the treatment of pain | |
| PH12020550341A1 (en) | Niraparib formulations | |
| PH12014500943A1 (en) | Combination treatment of cancer | |
| MX2016009666A (es) | Suministro topico de composiciones para la piel que tienen ph bajo. | |
| MX2014004960A (es) | Composiciones liposomales combinadas para terapia contra el cancer. | |
| WO2013090278A3 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
| MX2020013557A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. | |
| WO2012148174A3 (ko) | 탈모방지 및 발모촉진용 외용제 조성물 | |
| SG10201805552PA (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| MY194062A (en) | Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia | |
| MX2015017879A (es) | Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa. | |
| WO2012131341A3 (en) | Tight junctions modulators | |
| MX2022014763A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| SG11201808241WA (en) | Composition for skin moisturization or skin whitening, containing pentacyclic triterpene caffeic acid esters | |
| MX2015010594A (es) | Esteres de testosterona de cadena larga lipobalanceados para suministro oral. | |
| BR112014018426A8 (pt) | Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina | |
| GR1008819B (el) | Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου | |
| MX2009002985A (es) | Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (tsh). | |
| MX2015017124A (es) | Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer. | |
| TN2013000442A1 (en) | FORMULATION FOR ANTI-α4β7 ANTIBODY | |
| MX2019011749A (es) | Reduccion de la expresion de beta-catenina para potenciar la inmunoterapia. |